Inhibitors of Human Tumor-Expressed CCXCKR2
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 60/949,328, filed Jul 12, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,649,011 | Inhibitors of Human Tumor-Expressed CCXCKR2 In force · High confidence | Chemocentryx | In force | High confidence | ||
| US 7,572,600 | Enzymatic Activities in Chemokine-Mediated Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 7,683,176 | Triazolyl Pyridyl Benzenesulfonamides In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 7,718,683 | Triazolyl Phenyl Benzenesulfonamides In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 9,409,909 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES and N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES In force · Medium confidence | ChemoCentryx, Inc. | In force | Medium confidence | ||
| US 8,546,408 | Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 9,394,307 | Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 9,745,312 | Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation In force · High confidence | ChemoCentryx, Inc. | In force | High confidence | ||
| US 10,208,050 | Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 10,899,765 | Fused Heteroaryl Pyridyl and Phenyl Benzenesuflonamides as CCR2 Modulators for the Treatment of Inflammation In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| 33 more patents in this group · Pro | ||||||
10 of 43 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 43, including 14 expired and 4 expiring within the 18 months from Nov 16, 2026.
16 of these are in force and held by Chemocentryx, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.